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Abstract
Psychotic illnesses show variable responses to treatment. Determining the neurobiology underlying this is important for
precision medicine and the development of better treatments. It has been proposed that dopaminergic differences underlie
variation in response, with striatal dopamine synthesis capacity (DSC) elevated in responders and unaltered in non-
responders. We therefore aimed to test this in a prospective cohort, with a nested case-control comparison. 40 volunteers (26
patients with ﬁrst-episode psychosis and 14 controls) received an 18F-DOPA Positron Emission Tomography scan to
measure DSC (Kicer) prior to antipsychotic treatment. Clinical assessments (Positive and Negative Syndrome Scale, PANSS,
and Global Assessment of Functioning, GAF) occurred at baseline and following antipsychotic treatment for a minimum of
4 weeks. Response was deﬁned using improvement in PANSS Total score of >50%. Patients were followed up for at least
6 months, and remission criteria applied. There was a signiﬁcant effect of group on Kicer in associative striatum (F(2, 37)= 7.9,
p= 0.001). Kicer was signiﬁcantly higher in responders compared with non-responders (Cohen’s d= 1.55, p= 0.01) and
controls (Cohen’s d= 1.31, p= 0.02). Kicer showed signiﬁcant positive correlations with improvements in PANSS-positive
(r= 0.64, p < 0.01), PANSS negative (rho= 0.51, p= 0.01), and PANSS total (rho= 0.63, p < 0.01) ratings and a negative
relationship with change in GAF (r=−0.55, p < 0.01). Clinical response is related to baseline striatal dopaminergic
function. Differences in dopaminergic function between responders and non-responders are present at ﬁrst episode of
psychosis, consistent with dopaminergic and non-dopaminergic sub-types in psychosis, and potentially indicating a
neurochemical basis to stratify psychosis.
Introduction
A signiﬁcant proportion of people with schizophrenia and
other psychotic disorders show poor response to antipsychotic
treatment from illness onset [1, 2]. Poor therapeutic response is
associated with worse functional outcomes, higher healthcare
costs, and increased suicide risk [3]. Understanding the neu-
robiological basis of treatment response is fundamental to
developing better pharmacological treatments. A meta-analysis
of more than twenty molecular imaging studies showed both
striatal dopamine synthesis capacity (DSC) and release are
elevated in schizophrenia [4].This ﬁndings has also been seen
in ﬁrst-episode patients with affective, as well as schizo-
phreniform psychoses [5-7]. Striatal DSC is also elevated in
people at clinical high risk for psychosis [8, 9], and is speciﬁc
to the later development of psychosis [8, 10], progressively
increasing over the prodromal period [10], suggesting it is
linked to development of psychosis. However, it has been
proposed that there are at least two neurobiological sub-types
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underlying psychosis; a dopaminergic sub-type that shows
good response to dopamine receptor antagonists, and a non-
dopaminergic sub-type that shows poor response to dopamine
receptor blockade [11]. Supporting this, cross-sectional ima-
ging studies in chronic patients have found that patients with
treatment-resistant schizophrenia do not show elevated striatal
dopamine synthesis capacity relative to controls [12, 13].
Moreover, a post-mortem study of striatal levels of tyrosine
hydroxylase, an enzyme involved in dopamine synthesis,
found elevated levels in responders and no elevation in treat-
ment non-responders [14]. Another study measured synaptic
dopamine through indexing change in striatal dopamine D2/3
receptor radiotracer binding following pharmacological dopa-
mine depletion in schizophrenia. It found the magnitude of
alteration in radiotracer binding at baseline directly correlated
with reduction in positive symptoms following antipsychotic
treatment, indicating patients with lower synaptic dopamine
levels show a poorer response to antipsychotics [15]. These
studies suggest striatal DSC and baseline synaptic dopamine
are linked to antipsychotic response.
Prior studies relating DSC to treatment response in
psychosis included patients with chronic illness. As such it
is unknown if differences in dopaminergic measures
between antipsychotic responders and non-responders were
present from illness onset, suggesting a ‘trait’ feature con-
sistent with patient subgroups, or if differences had devel-
oped secondary to treatment effects or on-going symptoms,
suggesting a “state” feature. We aimed to address these
issues by prospectively examining the relationship between
DSC and subsequent response to antipsychotic treatment in
ﬁrst-episode psychosis patients with minimal antipsychotic
exposure. We focused on the associative striatum as the
studies in chronic patients indicate that this is the main
locus of dopaminergic alterations in psychosis [16], and for
differentiating responders/non-responders [12]. We tested
the following hypotheses:
1. Striatal dopamine synthesis capacity is higher in
patients with psychosis whose illness responds to
subsequent antipsychotic treatment, relative to non-
responders and healthy controls, and unaltered in non-
responders relative to controls.
2. Striatal dopamine synthesis capacity at presentation is
positively associated with subsequent improvement in
symptoms.
Materials and methods
Ethical approval
This study was approved by the East of England-Cambridge
East NHS Research Ethics Committee, and Administration
of Radioactive Substances Advisory Committee (ARSAC).
All participants provided informed written consent to
participate.
Participants
Informed consent was obtained from all participants.
Inclusion criteria
Patients were recruited from clinical services for people
presenting with a ﬁrst episode of psychosis in South and
West London. Inclusion criteria were: diagnosis of a psy-
chotic disorder according to ICD 10 criteria [17], and
requiring treatment with antipsychotic medication as
determined by the treating clinician.
International Statistical Classiﬁcation of Diseases and
related health problems version 10 (ICD 10) criteria were
used for diagnosis following entry into the study, at baseline
and follow-up.
Healthy volunteers were recruited through local media
from the same geographical area for normative compar-
isons. Inclusion criteria for controls were: no personal his-
tory of psychiatric illness (using the Structured Clinical
Interview for the DSM) [18] and no concurrent psycho-
tropic medication (ascertained through self-report).
Exclusion criteria for all subjects were: history of sig-
niﬁcant head trauma, dependence on illicit substances [19],
medical co-morbidity (other than minor illnesses), lifetime
use of antipsychotic drugs for longer than two weeks [20],
contra-indications to PET and MRI scanning (such as
pregnancy), or prescription of mood stabilizer medication.
Medication status
Subjects with psychosis were classiﬁed by antipsychotic
exposure as antipsychotic naïve, antipsychotic free (prior
oral antipsychotic medication but free of treatment for at
least 6 week (oral) or 6 months (depot, if relevant)) or
minimally treated (taking antipsychotic medication for two
weeks or less). Chlorpromazine-equivalent dose years were
calculated for prior antipsychotic exposure (using the
method described in [21]).
Clinical assessment
All patients were clinically assessed at baseline, and reas-
sessed after taking antipsychotic treatment at a therapeutic
dose as speciﬁed in the Maudsley Prescribing Guidelines
[19] for a minimum of four weeks, before determining
response. Four weeks was chosen as the minimum duration
of treatment based on evidence that most response to anti-
psychotic medication occurs within the ﬁrst four weeks
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[22, 23], including in ﬁrst-episode psychosis [24]. Fur-
thermore, non-response before four weeks is a strong pre-
dictor of subsequent non-response [25].
All participants received follow-up for at least six
months to determine if there had been a subsequent
response in patients who showed non-response at four
weeks. Choice of antipsychotic medication was
determined by the treating clinician in discussion with the
patient as per normal clinical care. Use of other psycho-
tropic medication (e.g., antidepressants and benzodiaze-
pines) was not an exclusion criterion for inclusion into the
study; though additional psychotropic medication (anti-
depressant or mood stabilizer medication) during the study
period (i.e., clinical follow-up) was an exclusion. Details of
medication prescribed are shown in Supplementary
Material.
Clinical measures were rated at baseline and follow-up
using the Positive and Negative Syndrome Scale (PANSS)
[26], Global Assessment of Functioning (GAF) [27], and
Clinical Global Impression Improvement scale (CGI-I) [28].
Ratings were conducted by clinicians blinded to patients’
striatal DSC. The duration of illness was calculated from the
onset of the ﬁrst psychotic symptoms as previously
described [29, 30].
Determination of response and non-response
Our primary deﬁnition of response was a total PANSS
reduction of ≥50% at the initial follow-up [31]. In line with
recommendations to report treatment effects using more
than one deﬁnition of response [31] we used two additional
approaches to deﬁning response.
The ﬁrst used the CGI-Improvement (CGI-I) scale [28].
This scale rates global clinical improvement from 1
= ”Very much improved” to 7= ”Very much worse”. A
rating of 1 or 2 (corresponding to “very much improved” or
“much improved”, respectively) corresponds to
clinically signiﬁcant improvement [32, 33]. The responder
group was deﬁned as a rating of 1 or 2 after treatment,
corresponding to a clinically meaningful improvement,
and the treatment non-responder group was deﬁned as
minimal improvement or worsening on the CGI-I. The
second approach used the Andreasen et al. [34] remission
criteria at 6 months to ascertain remission/ non-remission
status.
Medication concordance
To assess antipsychotic concordance, we used a multi-
source approach, requiring evidence of adequate adherence
on at least two of: antipsychotic levels in blood plasma,
pharmacy and electronic medical dispensing records,
reports from patients, and independent sources (a family
member/carer or health care professional) [35]. Subjects
were required to have taken at least 80% of prescribed
doses, in line with recommendations [36].
To compare antipsychotic exposure after the scan we
determined chlorpromazine-equivalent dose years (CPZ
dose years), using the method described by Andreasen et al.
[21]. In the case of drugs not covered by this (Lurasidone
and Amisulpride) we used the approach described by
Leucht et al. [37] and the Maudsley Prescribing Guidelines,
respectively.
18F-DOPA PET imaging and analysis
Imaging data were obtained on a Siemens Biograph 6
HiRez PET scanner (Siemens, Erlangen, Germany) in three-
dimensional mode. One hour before the scan participants
received 400 mg entacapone, a peripheral catechol-o-
methyl-transferase inhibitor, and 150 mg carbidopa, a per-
ipheral aromatic acid decarboxylase inhibitor, to prevent
formation of radiolabeled metabolites that may cross the
blood–brain barrier [38]. Participants were positioned in the
scanner with the orbitomeatal line parallel to the transaxial
plane of the tomograph. Head position was marked, mon-
itored and movement minimized using a head strap. After
acquiring a CT scan for attenuation correction, ~150MBq
of 18F-DOPA was administered by bolus intravenous
injection. PET data were acquired in 32 frames of increas-
ing duration over the 95 min scan (frame intervals: 8 × 15 s,
3 × 60 s, 5 × 120 s, 16 × 300 s).
Region-of-interest (ROI) analysis was conducted blind to
group status. Our primary endpoint was the striatal
inﬂux constant (Kicer, written as Ki in previous publications
[39]) in the associative striatum. SPM8 [40] was used to
automatically normalize a tracer-speciﬁc template [41, 42]
together with functional striatal ROI [43] and the
reference region (the cerebellum) to each individual
PET summation realigned image. Further details of
striatal sub-divisions are given in Supplementary Material.
Kicer was calculated using the Patlak-Gjedde graphical
approach adapted for a reference tissue input function.
This method has been shown to have good reliability for
measuring Kicer (intra-class correlation coefﬁcients
>0.85 for striatal ROIs) [41]. An exploratory voxel-wise
analysis was conducted to investigate sub-regional
differences in Kicer between groups (Supplementary
Material). Full details about tracer synthesis, data
acquisition and analysis are given in Supplementary
Material.
Individual striatal volumes were derived from the atlas
based segmentation and calculated as the total volume of
voxels in the striatal region-of-interest co-registered to the
individual PET summed images (further details are given
in Supplementary Material).
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Statistical Analysis
Statistical analyses were performed using SPSS, version 23
[44], and signiﬁcance set to p < 0.05 (two-tailed). Normality
of distribution was assessed using Shapiro–Wilkes test.
To test the ﬁrst hypothesis, we conducted a one-way ana-
lysis of variance (ANOVA) of the effect of group
(responders, non-responders and control groups using the
PANSS response criteria) on DSC, with post hoc pairwise
Tukey tests to determine if Kicer in associative striatum was
signiﬁcantly different between groups, in line with our
hypothesis that it is lower in non-responders relative to
responders.
To test the second hypothesis, we examined the rela-
tionship between baseline associative striatal Ki
cer
and percentage improvement in positive psychotic symp-
toms (PANSS positive). Secondary analyses tested rela-
tionships between baseline Ki
cer and improvement in other
clinical measures, using Pearson’s correlation coefﬁcients
for normally distributed data, (PANSS positive) and
Spearman’s correlation coefﬁcients for non-normally
distributed data (PANSS negative symptoms and GAF).
Cook’s distance test was used to investigate potential
outliers. ANOVA and independent sample t-tests were used
to determine group differences for parametric demographic
variables.
Percentage changes for GAF and PANSS were calcu-
lated, adjusting for minimum scores for the latter (7 for
positive and negative symptom sub-scales, 30 for total
symptoms) as shown here for the PANSS-positive symptom
subscale:
% change in positive PANSS ¼ baseline score 7ð Þ  follow up score 7ð Þð Þðbaseline score 7Þ  100
ð1Þ
Details of sample size calculation are given in Supple-
mentary Material.
Results
Demographics
Demographic details of participants are given in Table 1.
Forty volunteers participated (26 patients, 14 healthy
controls). There were no signiﬁcant differences between
Table 1 Demographic details
Variable Total patient
sample (N=26)
Responders
(N=13)
Non-responders
(N=13)
Controls
(N=14)
p-value
Gender (M;F) 22;4 10;3 12;1 10;4
Age, yearsa 25.31 (4.61) 24.38 (3.02) 26.23 (5.78) 24.29 (4.62) p= 0.48
Ethnicity
White 11 5 6 8
Black 9 4 5 3
Indian 2 2 0 2
Other 4 2 2 1
Duration of illness,
monthsb
19 (25.5) 12.5 (20.3) 24 (35) n/a p= 0.08
Antipsychotic naive,
n (%)/
14 (53.8%)/ 9 (69.2%)/ 5 (38.5)/
Free, n (%) 9 (34.6%) 3 (23.1%) 6 (46.2%)
Minimally treated, n
(%)
3 (11.5%) 1 (7.7%) 2 (15.4%)
Injected 146.02 144.62 147.41 146.92 p= 0.79
Activity, MBqc (12.1) (6.25) (16.18) (7.92)
Smoking status
Current 14 (53.8%) 9 (69.2%) 5 (38.5%) 3 (21.4%)
smoker 4 (15.4%) 1 (7.7%) 3 (23.1%) 3 (21.4%)
Past smoker 8 (30.8%) 3 (23.1%) 5 (385%) 8 (57.1%)
Never smoker
aAge is reported as mean (SD)
bDuration of illness is reported as Median (IQR)
cInjected Activity is reported as mean (SD)
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groups (responders, non-responders and controls) in age,
smoking status, radioactivity received, and between
responders and non-responders in illness duration, and prior
antipsychotic medication or antipsychotic exposure (mea-
sured in chlorpromazine dose years) between baseline scan
and clinical follow-up (all p-values >0.05). ICD-10 diag-
noses at baseline were: schizophrenia (n= 15), schizo-
phreniform disorder (n= 1) and bipolar affective disorder
(n= 10). At 6 month follow-up the only change in diag-
nosis was for the person with a diagnosis of schizophreni-
form disorder, which was changed to schizophrenia.
14 patients were antipsychotic naive, 9 medication-free,
and 3 were minimally treated at time of scanning (further
details in Supplementary Material). Of these, 13 subse-
quently met our primary (PANSS) criteria for treatment
response, and 13 for non-response. Group composition
varied little using the alternative response criteria (Supple-
mentary Material).
Baseline Kicer in treatment responders, non-
responders and controls
There were no differences in baseline symptom severity
between groups (Supplementary Table 1). There was no
signiﬁcant correlation between Kicer in associative striatum
and baseline PANSS-positive, negative, total symptoms, or
GAF score (all p-values >0.05).
Fig. 1 shows dopamine synthesis capacity (DSC) by
group. There was a signiﬁcant effect of group on Kicer in the
associative striatum (F(2, 37)= 7.9, p= 0.001). Post hoc
analyses, adjusted for multiple comparisons using the
Tukey test, indicated Kicer was elevated in responders
(mean= 13.45 × 10−3/min, SD= 0.78 × 10−3/min) relative
to both non-responders (mean= 12.12 × 10−3/min, SD=
0.93 × 10−3/min, p= 0.004) and control groups (mean=
12.17 × 10−3/min, SD= 1.14 × 10−3/min, p= 0.004). The
group effect remained signiﬁcant after adjusting for cere-
bellar uptake (Supplementary Material).
Cohen’s d effect size for elevation in responders relative
to non-responders was 1.55, and 1.31 relative to controls.
Kicer values for whole striatum and functional sub-divisions
are given in Supplementary Material. There were no sta-
tistically signiﬁcant differences in Kicer between non-
responders and controls (p= 0.99).
Striatal volumes
There was no effect of group on striatal volume (F(2, 37)=
2.22, p= 0.12), and pairwise comparisons also showed no
signiﬁcant difference in striatal volumes in responders
(mean= 17.27 cm3, SD= 17.8 cm3) relative to non-
responders (mean= 16.44 cm3, SD= 1.68 cm3, p= 0.38)
and controls (mean= 17.71 cm3, SD= 1.26 cm3, p= 0.75),
indicating that partial volume effects are unlikely to account
for our group differences.
Analysis in antipsychotic free individuals
In case antipsychotic treatment affected DSC, we conducted
an exploratory analysis, excluding people taking anti-
psychotics at time of the scan, leaving 12 responders, 11
non-responders and 14 controls. There was a signiﬁcant
effect of group on Kicer in associative striatum (F(2, 37)=
7.07, p= 0.001). Post hoc analyses, adjusted for multiple
comparisons using Tukey test, indicated signiﬁcant
differences between responders (mean= 13.5 × 10−3/min,
SD= 0.78 × 10−3/min), controls (p= 0.004), and non-
responders (mean= 12.27 × 10−3/min, SD= 0.93 × 10−3/
min, p= 0.01) and no signiﬁcant difference between non-
responders and controls (p= 0.96).
Voxel-wise analysis
Responders vs non-responders
The voxel-based analysis identiﬁed greater Ki
cer in respon-
ders relative to non-responders (deﬁned using the
PANSS criteria) in a voxel cluster with its peak in the left
putamen, and right caudate, both within the associative
striatum (Fig. 2, signiﬁcant at p < 0.05 corrected for multiple
comparisons using the family-wise error (FWE) rate
method). The non-responder group>responder group contrast
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Fig. 1 Mean dopamine synthesis capacity by group. Dopamine
synthesis capacity is elevated at baseline in patients who subsequently
respond to antipsychotic treatment, compared to controls and non-
responders (Cohen’s d effect size= 1.31 and 1.55, respectively). Error
bars indicate standard error of the mean
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revealed no signiﬁcant difference in any cluster or voxel,
even at an uncorrected statistical threshold of p < 0.05.
Responders vs healthy controls
The voxel-based analysis identiﬁed signiﬁcantly greater
Ki
cer in responders relative to controls in both left and right
caudate nuclei (Fig. 3, p < 0.05 FWE corrected for multiple
comparisons). The control group>responder group contrast
revealed no signiﬁcant difference, even at an uncorrected
statistical threshold of p < 0.05.
Non-responders vs healthy controls
The voxel-based analysis did not show any difference
between non-responders and healthy controls for either non-
responders>controls or controls>non-responders contrasts,
even at an uncorrected statistical threshold of p < 0.05.
Secondary analyses using alternative criteria for response
One patient assigned to the non-responder group using the
PANSS criteria for response, met the CGI criteria for
response. Thus there were 14 responders and 12 non-
responders in total using the CGI outcome measure. Never-
theless, using these groups, there was a signiﬁcant effect of
group status on Kicer, (F(2,37)= 6.05, p= 0.01). Kicer was
signiﬁcantly elevated in responders (mean= 13.32 × 10−3/
min, SD= 0.88 × 10-3/min) relative to both non-responder
(mean= 12.16 × 10−3/min, SD= 0.96 × 10−3/min, p= 0.01)
and control groups (mean= 12.17 × 10−3/min, SD= 1.14 ×
10−3/min, p= 0.02). There were no statistically signiﬁcant
differences in Kicer between non-responders and controls
(p= 0.99). We also investigated whether baseline Kicer was
associated with remission status at six months. There was a
signiﬁcant effect of Kicer on remission status at six months
(F(2, 37)= 6.05, p= 0.01). Kicer was signiﬁcantly elevated in
patients who subsequently met remission criteria (mean=
13.32 × 10-3/min, SD= 0.88 × 10−3/min) relative to those
who did not meet remission criteria (mean= 12.16 × 10−3/
min, SD= 0.96 × 10−3/min, p= 0.01).
The relationship between baseline dopamine
synthesis capacity and symptomatic and functional
response
There was a signiﬁcant positive correlation between asso-
ciative striatal Ki
cer and subsequent percentage improvement
0 1 2 3 4
T contrast
Fig. 2 Voxel-wise analysis of
treatment responders compared
to non-responders. Increased
dopamine synthesis capacity,
relative to non-responder
patients (N= 13), in patients
who respond to treatment
(N= 13). The most signiﬁcant
increase was in voxels in right
caudate (Peak MNI coordinates
x= 18, y= 20, z= 2; pFWE corr
= 0.026) and left putamen (Peak
MNI coordinates x=−24,
y= 8, z=−2; pFWE corr= 0.027)
Fig. 3 Voxel-wise analysis of
treatment responders compared
to controls. Increased dopamine
synthesis capacity, relative to
controls (N= 14), in patients
who respond to treatment
(N= 13). The most signiﬁcant
increase was in a voxel in both
left (Peak MNI coordinates
x=−12, y= 16, z= 6; pFWE corr
< 0.001) and right caudate (Peak
MNI coordinates x= 14, y= 18,
z= 0; pFWE corr < 0.001)
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in PANSS-positive symptoms following treatment (r=
0.64, p < 0.001; Fig. 4). The relationship remained sig-
niﬁcant after removal of two potential outliers (r= 0.69,
p < 0.01). The effect remained signiﬁcant after partial cor-
relation for dosage of antipsychotic medication received
during treatment episode (CPZ dose years) (r= 0.44,
p < 0.05). Whilst there was no signiﬁcant difference in ill-
ness duration between responders and non-responders, non-
responders had longer illness duration in absolute terms. To
determine if this inﬂuenced the relationship with symptom
response, we conducted a partial correlation including ill-
ness duration. The relationship between Kicer and positive
symptoms remained signiﬁcant after adjusting for illness
duration (r= 0.66, p < 0.01).
Secondary analyses showed a signiﬁcant positive correla-
tion between baseline associative striatal Ki
cer and percentage
improvement in PANSS negative symptoms (rho= 0.51, p=
0.01), PANSS total symptoms (rho= 0.63, p < 0.01) and a
signiﬁcant negative correlation with GAF change (r=−0.55,
p < 0.01). Kicer explained 41%, 26% and 40% of the variance
for PANSS-positive, negative and total symptom change
respectively, and 30% of variance in GAF improvement.
These correlations were numerically stronger when
analysis was limited to antipsychotic naïve subjects for
percentage change in PANSS-positive symptoms (r= 0.77;
p < 0.01), for percentage change in PANSS negative
symptom (rho= 0.65; p= 0.01), for percentage change in
total PANSS symptoms (rho= 0.76; p < 0.01), and for GAF
improvement (r=−0.79; p < 0.01).
Discussion
Our main ﬁnding is that striatal dopamine synthesis capacity
is signiﬁcantly higher in patients with ﬁrst-episode
psychosis who subsequently respond to antipsychotic
treatment compared to those with a subsequent poor
response, with a large effect size (Cohen’s d= 1.55).
Striatal dopamine synthesis capacity explained >40% of the
variance in subsequent positive psychotic symptom change
following treatment. This suggests dopamine dysfunction
before starting treatment is linked to likelihood of
responding to antipsychotic treatment, such that those with
greatest dopamine elevation during an acute psychotic
episode are most likely to show symptomatic improvement
during treatment.
This extends a prior cross-sectional study showing ele-
vated DSC in chronic treatment-responsive patients relative
to non-responders [13], to show prospectively that dopa-
mine function is linked to response in ﬁrst-episode patients.
Our ﬁndings suggest differences between responders and
non-responders are not secondary to illness chronicity or
long-term antipsychotic exposure. Furthermore, the effect
size for the differences that we identiﬁed was similar to
patients with chronic psychoses, suggesting the magnitude
of differences may not change markedly over illness course
or with long-term medication exposure, although long-
itudinal studies are required to deﬁnitively test this.
These ﬁndings also extend other recent evidence that
response to antipsychotic treatment in ﬁrst-episode patients
is related to alterations in striatal functional connectivity
[45–47], and lower baseline striatal D2/3 receptor availability
between responders and non-responders [48]. It has been
speculated that lower baseline D2/3 receptor availability
could reﬂect greater synaptic dopamine levels in responders
[48], which would be consistent with our ﬁnding that
responders also have elevated dopamine synthesis capacity.
However, people with established schizophrenia (both
responsive and resistant to treatment) show no differences in
D2/3 receptor availability compared with healthy controls
[49]. Taken with previous molecular imaging studies
showing dopamine D2/3 receptor occupancy by anti-
psychotics is required for therapeutic response [33, 50], our
ﬁndings indicate D2/3 receptor blockade is acting to oppose
the consequences of presynaptic dopamine dysfunction [51].
Strengths and limitations
A strength of this study is its prospective design in ﬁrst-
episode patients predominantly free of antipsychotic medi-
cation. Our measure for deﬁning response has good clinical
validity [52], and was reinforced by ﬁnding similar results
using other outcomes. A potential limitation is that patients
received a range of different antipsychotics. However, both
responder and non-responders received similar anti-
psychotics (Supplementary Material), and there is good
evidence that these compounds have similar effectiveness
[24]. Furthermore, partial correlation for effects of
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Fig. 4 Relationship between baseline dopamine synthesis capacity and
subsequent antipsychotic response. A positive association was found
between associative striatum dopamine synthesis capacity and sub-
sequent improvement in positive psychotic symptoms, measured using
the PANSS-positive subscale
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antipsychotic exposure on the correlation between Kicer and
PANSS-positive symptom improvement did not change our
results, making it unlikely that the differences in response
were due to differences in treatment exposure. Three of
26 subjects (one responder and two non-responders) had
received a short course of antipsychotic treatment prior to
imaging, which could have conceivably affected DSC. The
preclinical animal literature suggests that, by blocking D2
autoreceptors, acute antipsychotic use would increase pre-
synaptic dopamine synthesis [53, 54], but chronic use leads
to reduced dopamine neuron ﬁring, which could be expec-
ted to reduce dopamine synthesis [53]. The acute effects of
antipsychotics on DSC in healthy volunteers are incon-
sistent [55, 56]. The only longitudinal study in patients
showed a reduction in striatal dopamine synthesis after
approximately 5 weeks of haloperidol treatment [57].
Overall it remains unclear what effect the treatment these
patients had received would have had on dopamine synth-
esis capacity. In any event, our ﬁndings remained sig-
niﬁcant when group analyses excluded minimally treated
patients, and when correlation analyses were restricted to
antipsychotic naive subjects, indicating that this does not
account for the alterations we report. Our study design did
not enable us to investigate the relationship between DSC
and the development of treatment resistance, which would
require non-responders to be switched to a second
antipsychotic.
Our study was in patients presenting with their ﬁrst
psychotic episode, and included patients with diagnoses of
schizophrenia and bipolar affective disorder, in line with
other ﬁrst-episode studies [46, 7]. As such our results relate
to psychosis across these disorder, speciﬁcally positive
psychotic symptoms. Nevertheless, it is important to
recognize that diagnoses can change over the ﬁrst few years
of illness [58] and further follow-up of our sample is
required to determine the ﬁnal diagnoses and if ﬁndings are
speciﬁc to particular psychotic disorders.
Finally, we did not measure the plasma input function so
cannot exclude differences in peripheral 18F-DOPA meta-
bolism or other factors affecting delivery of 18F-DOPA to
brain tissue. However, we blocked peripheral metabolism
and previous studies have not detected differences in psy-
chotic disorders [59, 60]. Differences in blood ﬂow could
also inﬂuence ﬁndings. However, the reference region
approach we used accounts for global differences in
18F-DOPA delivery [60], and co-varying for tracer uptake in
the cerebellum (SUV) did not change the results.
Biological meaning of our ﬁndings
Kicer indexes a number of biological processes in vivo,
including the uptake of radiolabeled DOPA into dopamine
neurons, its conversion into radiolabeled dopamine by
DOPA decarboxylase, and its storage in vesicles in pre-
synaptic dopamine nerve terminals [54]. As such it does not
necessarily imply increased dopamine synthesis, as the
measure is also sensitive to other processes such as
L-DOPA transport into the neuron, vesicular storage, and
dopamine catabolism. Moreover, the rate-limiting step for
dopamine synthesis in brain is the conversion of tyrosine
into L-DOPA by tyrosine hydroxylase. Nevertheless,
DOPA decarboxylase is a regulated enzyme in the synthesis
of dopamine, may be rate limiting in some circumstances,
and dopamine levels are sensitive to DOPA decarboxylase
activity [7, 60]. Moreover, studies using challenge para-
digms indicate that patients with psychotic disorders show
more striatal dopamine release than healthy controls [61,
62], dopamine turnover is elevated in schizophrenia [63]
and greater synaptic dopamine levels are linked to greater
subsequent improvement in psychotic symptoms [15].
Thus, taken with this prior evidence, the most parsimonious
explanation of our ﬁndings is that increased dopamine
synthesis capacity is linked to subsequent treatment
response in psychotic disorders (see Howes et al. [4] for a
further discussion). Nevertheless, future studies of tyrosine
hydroxylase activity in patients would be useful to deter-
mine if this is altered in vivo and provide further evidence
that dopamine synthesis is related to treatment response.
Implications and Future directions
Our ﬁndings that antipsychotic treatment response in psy-
chosis is related to pre-existing presynaptic dopamine
function provides an explanation for the effectiveness of
antipsychotics, which antagonize dopamine receptors [64],
and their ineffectiveness in the non-responders, who did not
show marked dopaminergic dysfunction as a group. Our
ﬁndings suggest novel treatments with a mechanism of
action that does not involve dopaminergic blockade may be
indicated in this subgroup. These ﬁndings also suggest
neuroimaging measures, in addition to clinical variables,
could be used to help stratify patients with psychosis to
predict future antipsychotic response and, more importantly,
non-response. This could facilitate earlier introduction of
alternatives to conventional treatment, such as clozapine, or
novel interventions that do not depend on dopamine
receptor antagonism.
Further work is required to determine the accuracy of
F-DOPA PET in predicting response, and whether this is
sufﬁcient on its own or additional clinical measures are
required. While 18-F-DOPA PET is not widely available,
limiting its current use as a biomarker, the increasing
availability of PET scanners and the relatively long half-life
of the ligand, allowing it to be manufactured centrally and
delivered to many sites, means this is likely to change in the
next few years.
S. Jauhar et al.
In conclusion, striatal dopamine synthesis capacity is
elevated in patients with ﬁrst-episode psychosis who sub-
sequently respond to treatment, but not in those who do not
respond, and the level of dopamine synthesis capacity is
associated with degree of subsequent antipsychotic
response.
Acknowledgements We would like to thank the patients who took part
in the study, and staff from Early Intervention Services, speciﬁcally Dr
Rahaman, Dr Montgomery and Dr Morrison. Professor O.D.H. has
received speaker bureau honoraria and charitable reseach funding from
AstraZeneca, BMS, Eli Lilly, Jannsen-Cilag, and Roche. Dr O.D.H.
work has been funded by the Medical Research Council, UK, and
Wellcome Trust. Professor S.K. has received grant support from
AstraZeneca and GlaxoSmithKline and has served as consultant and/or
speaker for AstraZeneca, Bioline, BMS-Otsuka, Eli Lilly, Janssen
(J&J), Lundbeck, NeuroSearch, Pﬁzer, Roche, Servier, and Solvay
Wyeth. Dr Howes is funded by Medical Research Council grant MC-
A656-5QD30, Maudsley Charity grant 666, support from the US Brain
& Behavior Research Foundation, and Wellcome Trust grant 094849/
Z/10/Z to Dr Howes and the National Institute for Health Research
Biomedical Research Centre at South London and Maudsley National
Health Service Foundation Trust and King’s College London. Dr
Veronese is funded by the National Institute for Health Research
Biomedical Research Centre at South London and Maudsley National
Health Service Foundation Trust and King’s College London. Dr
Jauhar is is funded by the National Institute for Health Research
Biomedical Research Centre at South London and Maudsley National
Health Service Foundation Trust and King’s College London, and a
JMAS SIM Fellowship from the Royal College of Physicians,
Edinburgh.
Conﬂict of interest Professor Howes has received speaker bureau
honoraria and charitable reseach funding from Astra-Zeneca, BMS, Eli
Lilly, Jannsen-Cilag, and Roche. Dr McGuire reported receiving
investigator-initiated research funding from or participating in advi-
sory or speaker meetings organized by Sunovion, Janssen, GW
Pharmaceuticals, Takeda, and Roche. Professor Shitij Kapur has
received grant support from AstraZeneca and GlaxoSmithKline and
has served as consultant and/or speaker for AstraZeneca,Bioline,
BMS-Otsuka, Eli Lilly, Janssen (J&J), Lundbeck, NeuroSearch, Pﬁzer,
Roche, Servier, and Solvay Wyeth.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H,
Kollack-Walker S, et al. Early response to antipsychotic
therapy as a clinical marker of subsequent response in the
treatment of patients with ﬁrst-episode psychosis. Psychiatry Res.
2011;187:42–48.
2. Lally J, Ajnakina O, Forti MD, Trotta A, Demjaha A, Kolliakou
A, et al. Two distinct patterns of treatment resistance: clinical
predictors of treatment resistance in ﬁrst-episode schizophrenia
spectrum psychoses. Psychol Med. 2016;46:3231–40.
3. Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The
social and economic burden of treatment-resistant schizophrenia: a
systematic literature review. Int Clin Psychopharmacol.
2014;29:63–76.
4. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-
Dargham A, et al. The nature of dopamine dysfunction in schi-
zophrenia and what this means for treatment: meta-analysis of
imaging studies. Arch Gen Psychiatry. 2012;69:776–86.
5. Hietala J, Syvalahti E, Vuorio K, Nagren K, Lehikoinen P,
Ruotsalainen U, et al. Striatal D2 dopamine receptor character-
istics in neuroleptic-naive schizophrenic patients studied with
positron emission tomography. Arch Gen Psychiatry.
1994;51:116–23.
6. Hietala J, Syvälahti E, Vilkman H, Vuorio K, Räkköläinen V,
Bergman J, et al. Depressive symptoms and presynaptic dopamine
function in neuroleptic-naive schizophrenia. Schizophr Res.
1999;35:41–50.
7. Jauhar S, Nour MM, Veronese M, Rogdaki M, Bonoldi I, Azis M,
et al. A test of the transdiagnostic dopamine hypothesis of psy-
chosis using positron emission tomographic imaging in bipolar
affective disorder and schizophrenia. JAMA Psychiatry.
2017;74:1206–13. https://doi.org/10.1001/jamapsychiatry.2017.
2943
8. Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Val-
maggia LR, et al. Dopamine synthesis capacity before onset of
psychosis: a prospective [18F]-DOPA PET imaging study. Am J
Psychiatry. 2011;168:1311–7.
9. Egerton A, Chaddock CA, Winton-Brown TT, Bloomﬁeld MAP,
Bhattacharyya S, Allen P, et al. Presynaptic striatal dopamine
dysfunction in people at ultra-high risk for psychosis: ﬁndings in a
second cohort. Biol Psychiatry. 2013;74:106–12.
10. Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, et al.
Progressive increase in striatal dopamine synthesis capacity as
patients develop psychosis: a PET study. Mol Psychiatry.
2011;16:885–6.
11. Howes OD, Kapur S. A neurobiological hypothesis for the clas-
siﬁcation of schizophrenia: type A (hyperdopaminergic) and type
B (normodopaminergic). Br J Psychiatry. 2014;205:1–3.
12. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD.
Dopamine synthesis capacity in patients with treatment-resistant
schizophrenia. Am J Psychiatry. 2014;169:1203–10. https://ajp.
psychiatryonline.org/doi/10.1176/appi.ajp.2012.12010144
13. Kim E, Howes OD, Veronese M, Beck K, Seo S, Park JW, et al.
Presynaptic dopamine capacity in patients with treatment-resistant
schizophrenia taking clozapine: an [18F]DOPA PET Study.
Neuropsychopharmacology. 2017;42:941–50.
14. Roberts RC, Roche JK, Conley RR, Lahti AC. Dopaminergic
synapses in the caudate of subjects with schizophrenia: relation-
ship to treatment response. Synapse. 2009;63:520–30.
15. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R,
Kegeles LS, et al. Increased baseline occupancy of D2 receptors
by dopamine in schizophrenia. Proc Natl Acad Sci USA.
2000;97:8104–9.
16. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB,
Slifstein M, et al. Increased Synaptic Dopamine Function in
Associative Regions of the Striatum in Schizophrenia. Arch Gen
Psychiatry. 2010;67:231–9.
17. World Health Organization The ICD-10 classiﬁcation of mental
and behavioural disorders: diagnostic criteria for research.
World Health Organization, Geneva, 1993.
Determinants of treatment response in ﬁrst-episode psychosis: an 18F-DOPA PET study
18. First MB Structured Clinical Interview for the DSM (SCID). In:
The Encyclopedia of Clinical Psychology. John Wiley & Sons,
Inc., USA, 2014
19. Taylor D, Paton C, Kapur S, (eds). The Maudsley Prescribing
Guidelines in Psychiatry. 11th Edition. West Sussex: Wiley-
Blackwell: Chichester; 2012.
20. Leucht S, Winter-van Rossum I, Heres S, Arango C, Fleisch-
hacker WW, Glenthøj B, et al. The optimization of treatment and
management of schizophrenia in Europe (OPTiMiSE) trial:
rationale for its methodology and a review of the effectiveness of
switching antipsychotics. Schizophr Bull. 2015;41:549–58.
21. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho B-C.
Antipsychotic dose equivalents and dose-years: a standardized
method for comparing exposure to different drugs. Biol Psy-
chiatry. 2010;67:255–62.
22. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset
hypothesis of antipsychotic action: a hypothesis tested and
rejected. Arch Gen Psychiatry. 2003;60:1228.
23. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-
Walker S, Zhou W, et al. Early response to antipsychotic
drug therapy as a clinical marker of subsequent response in the
treatment of schizophrenia. Neuropsychopharmacology.
2010;35:581–90.
24. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe
Y, Keet IP, et al. Effectiveness of antipsychotic drugs in ﬁrst-
episode schizophrenia and schizophreniform disorder: an open
randomised clinical trial. Lancet. 2008;371:1085–97.
25. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-
Walker S, Sniadecki JL, et al. Predicting response to atypical
antipsychotics based on early response in the treatment of schi-
zophrenia. Schizophr Res. 2008;102:230–40.
26. Kay SR, Flszbein A, Opfer LA. The positive and negative syn-
drome scale (PANSS) for schizophrenia. Schizophr Bull.
1987;13:261.
27. Association AP, DSM-IV APA on. Diagnostic and statistical
manual of mental disorders: DSM-IV-TR. American Psychiatric
Publishing, Inc, USA, 2000.
28. Busner J, Targum SD. The clinical global impressions scale.
Psychiatry. 2007;4:28–37.
29. Sarpal DK, Robinson DG, Fales C, Lencz T, Argyelan M,
Karlsgodt KH, et al. Relationship between duration of untreated
psychosis and intrinsic corticostriatal connectivity in patients
with early phase Schizophrenia. Neuropsychopharmacology.
2017;42:2214–21.
30. Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M, Miettunen J.
Duration of untreated psychosis as predictor of long-term outcome
in schizophrenia: systematic review and meta-analysis. Br J Psy-
chiatry. 2014;205:88–94.
31. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Deﬁnitions
of response and remission in schizophrenia: recommendations for
their use and their presentation. Acta Psychiatr Scand.
2009;119:7–14.
32. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR.
What does the PANSS mean? Schizophr Res. 2005;79:231–8.
33. Kapur S. Relationship between dopamine D2 occupancy,
clinical response, and side effects: A Double-Blind PET
Study of First-Episode Schizophrenia. Am J Psychiatry.
2000;157:514–20.
34. Andreasen NC. Remission in Schizophrenia: proposed criteria and
rationale for consensus. Am J Psychiatry. 2005;162:441–9.
35. Sajatovic M, Velligan DI, Weiden PJ, Valenstein MA, Ogedegbe
G. Measurement of psychiatric treatment adherence. J Psychosom
Res. 2010;69:591–9.
36. Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van
Beveren NJM, Birnbaum ML, et al. Treatment-Resistant Schizo-
phrenia: Treatment Response and Resistance in Psychosis
(TRRIP) working group consensus guidelines on diagnosis and
terminology. Am J Psychiatry. 2016;174:216–29.
37. Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM.
Dose equivalents for second-generation antipsychotics: the mini-
mum effective dose method. Schizophr Bull. 2014;40:314–26.
38. Cumming P, Léger GC, Kuwabara H, Gjedde A. Pharmacoki-
netics of plasma 6-[18F]ﬂuoro-L-3,4-dihydroxyphenylalanine
([18F]Fdopa) in humans. J Cereb Blood Flow Metab.
1993;13:668–75.
39. Jauhar S, Veronese M, Rogdaki M, Bloomﬁeld M, Natesan S,
Turkheimer F, et al. Regulation of dopaminergic function: an
[18F]-DOPA PET apomorphine challenge study in humans.
Transl Psychiatry. 2017;7:e1027.
40. SPM - Statistical Parametric Mapping. http://www.ﬁl.ion.ucl.ac.
uk/spm/. Accessed 5 Oct 2016.
41. Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD. The
test-retest reliability of 18F-DOPA PET in assessing striatal and
extrastriatal presynaptic dopaminergic function. Neuroimage.
2010;50:524–31.
42. Howes OD, Montgomery AJ, Asselin M, Murray RM, Valli I,
Tabraham P, et al. Elevated Striatal Dopamine Function Linked to
Prodromal Signs of Schizophrenia. Arch Gen Psychiatry.
2009;66:13–20.
43. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang D-R,
Huang Y, et al. Imaging Human Mesolimbic Dopamine Trans-
mission With Positron Emission Tomography. Part II:
Amphetamine-Induced Dopamine Release in the Functional
Subdivisions of the Striatum. J Cereb Blood Flow Metab.
2003;23:285–300.
44. IBM Downloading IBM SPSS Statistics 21 - United States. 2012.
http://www-01.ibm.com/support/docview.wss?uid=sw
g24032236. Accessed 3 Jun 2015.
45. Fornito A, Yoon J, Zalesky A, Bullmore ET, Carter CS. General
and speciﬁc functional connectivity disturbances in ﬁrst-episode
schizophrenia during cognitive control performance. Biol Psy-
chiatry. 2011;70:64–72.
46. Sarpal DK, Argyelan M, Robinson DG, Szeszko PR, Karlsgodt
KH, John M, et al. Baseline striatal functional connectivity as a
predictor of response to antipsychotic drug treatment. Am J Psy-
chiatry. 2015;173:69–77.
47. Sarpal DK, Robinson DG, Lencz T, Argyelan M, Ikuta T,
Karlsgodt K, et al. Antipsychotic treatment and functional con-
nectivity of the striatum in ﬁrst-episode schizophrenia. JAMA
Psychiatry. 2015;72:5–13.
48. Wulff S, Pinborg LH, Svarer C, Jensen LT, Nielsen MØ, Allerup
P, et al. Striatal D(2/3) binding potential values in drug-naïve ﬁrst-
episode Schizophrenia patients correlate with treatment outcome.
Schizophr Bull. 2015;41:1143–52.
49. Lawrie SM, Ingle GT, Santosh CG, Rogers AC, Rimmington JE,
Naidu KP, et al. Magnetic resonance imaging and single photon
emission tomography in treatment-responsive and treatment-
resistant schizophrenia. Br J Psychiatry. 1995;167:202–10.
50. Dopamine blockade and clinical response: evidence for two bio-
logical subgroups of schizophrenia: Am J Psychiatry. 146: 7.
http://ajp.psychiatryonline.org/doi/abs/10.1176/ajp.146.7.905.
51. Howes OD, Murray RM. Schizophrenia: an integrated
sociodevelopmental-cognitive model. Lancet. 2014;383:1677–87.
52. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR.
Linking the PANSS, BPRS, and CGI: clinical implications.
Neuropsychopharmacology. 2006;31:2318–25.
53. Bunney BS, Grace AA. Acute and chronic haloperidol treatment:
comparison of effects on nigral dopaminergic cell activity. Life
Sci. 1978;23:1715–27.
54. Danielsen EH, Smith D, Hermansen F, Gjedde A, Cumming P.
Acute neuroleptic stimulates DOPA decarboxylase in porcine
brain in vivo. Synapse. 2001;41:172–5.
S. Jauhar et al.
55. Ito H, Takano H, Takahashi H, Arakawa R, Miyoshi M, Kodaka
F, et al. Effects of the antipsychotic risperidone on dopamine
synthesis in human brain measured by positron emission tomo-
graphy with l-[β-11C]DOPA: a stabilizing effect for dopaminergic
neurotransmission? J Neurosci. 2009;29:13730–4.
56. Vernaleken I, Kumakura Y, Cumming P, Buchholz H-G, Siess-
meier T, Stoeter P, et al. Modulation of [18F]ﬂuorodopa (FDOPA)
kinetics in the brain of healthy volunteers after acute haloperidol
challenge. Neuroimage. 2006;30:1332–9.
57. Gründer G, Vernaleken I, Müller MJ, Davids E, Heydari N,
Buchholz HG, et al. Subchronic haloperidol downregulates
dopamine synthesis capacity in the brain of schizophrenic patients
in vivo. Neuropsychopharmacology. 2003;28:787–94.
58. Heslin M, Lomas B, Lappin JM, Donoghue K, Reininghaus U,
Onyejiaka A, et al. Diagnostic change 10 years after a ﬁrst episode
of psychosis. Psychol Med. 2015;45:2757–69.
59. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H,
Andermann F, et al. Elevated dopa decarboxylase activity in living
brain of patients with psychosis. Proc Natl Acad Sci USA.
1994;91:11651–4.
60. Kumakura Y, Cumming P PET studies of cerebral levodopa
metabolism: a review of clinical ﬁndings and modeling approa-
ches. Neuroscientist. 2009;15:635–50.
61. Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau I,
et al. Increased stress-induced dopamine release in psychosis. Biol
Psychiatry. 2012;71:561–7.
62. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza CD,
Erdos J, et al. Single photon emission computerized tomography
imaging of amphetamine-induced dopamine release in
drug-free schizophrenic subjects. Proc Natl Acad Sci USA.
1996;93:9235–40.
63. Kumakura Y, Cumming P, Vernaleken I, Buchholz H-G, Siess-
meier T, Heinz A, et al. Elevated [18F]ﬂuorodopamine turnover in
brain of patients with schizophrenia: an [18F]ﬂuorodopa/positron
emission tomography study. J Neurosci. 2007;27:8080–7.
64. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S.
Mechanisms underlying psychosis and antipsychotic treatment
response in Schizophrenia: insights from PET and SPECT ima-
ging. Curr Pharm Des. 2009;15:2550–9.
Determinants of treatment response in ﬁrst-episode psychosis: an 18F-DOPA PET study
